List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7572737/publications.pdf Version: 2024-02-01



ΜΑΡΙΟ ΜΙΕΙΤΛΟ

#	Article	IF	CITATIONS
1	The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: Beyond removal of blue nodes. Gynecologic Oncology, 2012, 125, 531-535.	1.4	353
2	Endometrial cancer: A review and current management strategies: Part I. Gynecologic Oncology, 2014, 134, 385-392.	1.4	339
3	Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2012, 30, 3786-3791.	1.6	317
4	Endometrial cancer: A review and current management strategies: Part II. Gynecologic Oncology, 2014, 134, 393-402.	1.4	305
5	Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. Gynecologic Oncology, 2014, 133, 274-277.	1.4	246
6	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. JAMA Oncology, 2016, 2, 1434.	7.1	189
7	A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecologic Oncology, 2014, 134, 455-461.	1.4	180
8	The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecologic Oncology, 2009, 115, 236-238.	1.4	164
9	Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecologic Oncology, 2003, 91, 209-212.	1.4	159
10	Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer, 2004, 101, 1455-1462.	4.1	152
11	Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecologic Oncology, 2016, 140, 394-399.	1.4	139
12	ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Modern Pathology, 2018, 31, 674-684.	5.5	130
13	A nomogram to predict postresection 5â€year overall survival for patients with uterine leiomyosarcoma. Cancer, 2012, 118, 660-669.	4.1	126
14	Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecologic Oncology, 2009, 113, 105-108.	1.4	121
15	Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. Journal of Clinical Oncology, 2009, 27, 2066-2072.	1.6	119
16	Low-Volume Lymph Node Metastasis Discovered During Sentinel Lymph Node Mapping for Endometrial Carcinoma. Annals of Surgical Oncology, 2016, 23, 1653-1659.	1,5	114
17	SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study. International Journal of Gynecological Cancer, 2019, 29, 829-834.	2.5	102
18	Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecologic Oncology, 2010, 116, 424-429.	1.4	92

#	Article	IF	CITATIONS
19	Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. Gynecologic Oncology, 2013, 130, 452-456.	1.4	87
20	Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. Annals of Surgical Oncology, 2016, 23, 196-202.	1.5	86
21	Surgical Resection of Pulmonary and Extrapulmonary Recurrences of Uterine Leiomyosarcoma. Gynecologic Oncology, 2002, 87, 287-294.	1.4	84
22	Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. Gynecologic Oncology, 2017, 147, 541-548.	1.4	82
23	Expanding the Indications for Radical Trachelectomy. International Journal of Gynecological Cancer, 2013, 23, 1092-1098.	2.5	77
24	Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecologic Oncology, 2004, 93, 301-306.	1.4	76
25	Sentinel lymph node mapping with pathologic ultrastaging: A valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecologic Oncology, 2013, 131, 714-719.	1.4	76
26	The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications. Gynecologic Oncology, 2014, 133, 552-555.	1.4	75
27	Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecologic Oncology, 2012, 124, 558-562.	1.4	73
28	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. Gynecologic Oncology, 2015, 138, 246-251.	1.4	71
29	Ovarian clear cell carcinoma, outcomes by stage: The MSK experience. Gynecologic Oncology, 2015, 139, 236-241.	1.4	70
30	Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecologic Oncology, 2008, 111, 244-248.	1.4	69
31	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. Annals of Surgical Oncology, 2016, 23, 2522-2528.	1.5	69
32	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. Journal of Clinical Oncology, 2021, 39, 3623-3632.	1.6	69
33	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Vulvovaginal Melanomas. International Journal of Gynecological Cancer, 2014, 24, S117-S122.	2.5	67
34	Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecologic Oncology, 2004, 95, 181-188.	1.4	66
35	Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy. Gynecologic Oncology, 2018, 151, 235-242.	1.4	63
36	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecologic Oncology, 2019, 154, 516-523.	1.4	62

#	Article	IF	CITATIONS
37	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecologic Oncology, 2020, 156, 147-153.	1.4	61
38	Radical Trachelectomy for the Treatment of Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2020, 136, 533-542.	2.4	61
39	Cost-Effectiveness Analysis of Robotically Assisted Laparoscopy for Newly Diagnosed Uterine Cancers. Obstetrics and Gynecology, 2014, 123, 1031-1037.	2.4	60
40	Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers. Gynecologic Oncology, 2018, 148, 480-484.	1.4	60
41	Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecologic Oncology, 2012, 125, 409-413.	1.4	58
42	Uterine serous carcinoma. Gynecologic Oncology, 2021, 162, 226-234.	1.4	58
43	A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease. Gynecologic Oncology, 2016, 142, 139-143.	1.4	57
44	A Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer. Oncologist, 2009, 14, 835-839.	3.7	56
45	Surgical Management of Recurrent Ovarian Cancer. Seminars in Oncology, 2009, 36, 106-111.	2.2	55
46	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. Gynecologic Oncology, 2017, 145, 15-20.	1.4	55
47	Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. Gynecologic Oncology, 2020, 156, 591-597.	1.4	54
48	Lower extremity lymphedema in patients with gynecologic malignancies. International Journal of Gynecological Cancer, 2020, 30, 252-260.	2.5	53
49	Postoperative Pain Medication Requirements in Patients Undergoing Computer-Assisted ("Roboticâ€) and Standard Laparoscopic Procedures for Newly Diagnosed Endometrial Cancer. Annals of Surgical Oncology, 2013, 20, 3561-3567.	1.5	48
50	Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk. American Journal of Obstetrics and Gynecology, 2010, 203, 349.e1-349.e6.	1.3	47
51	Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping. Annals of Surgical Oncology, 2017, 24, 1965-1971.	1.5	47
52	Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncology, 2022, 8, 618.	7.1	46
53	Management of Vulvar and Vaginal Melanomas: Current and Future Strategies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e277-e281.	3.8	45
54	Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecologic Oncology, 2003, 91, 123-129.	1.4	43

#	Article	IF	CITATIONS
55	Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. Annals of Surgical Oncology, 2016, 23, 2192-2198.	1.5	43
56	A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. Gynecologic Oncology, 2017, 145, 230-235.	1.4	43
57	Factors influencing the adoption of the sentinel lymph node technique for endometrial cancer staging: an international survey of gynecologic oncologists. International Journal of Gynecological Cancer, 2019, 29, 60-67.	2.5	43
58	Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma. Gynecologic Oncology, 2020, 156, 62-69.	1.4	43
59	A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer. International Journal of Gynecological Cancer, 2017, 27, 743-747.	2.5	42
60	When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic. Gynecologic Oncology, 2020, 158, 236-243.	1.4	42
61	Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: A multi-institutional study. Gynecologic Oncology, 2014, 134, 253-256.	1.4	41
62	Histological features associated with occult lymph node metastasis in <scp>FIGO</scp> clinical stage <scp>I</scp> , grade <scp>I</scp> endometrioid carcinoma. Histopathology, 2014, 64, 389-398.	2.9	40
63	Fellowship learning curve associated with completing a robotic assisted total laparoscopic hysterectomy. Gynecologic Oncology, 2014, 132, 102-106.	1.4	40
64	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecologic Oncology Reports, 2016, 16, 42-46.	0.6	40
65	Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm. Gynecologic Oncology, 2019, 155, 177-185.	1.4	38
66	Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. Gynecologic Oncology, 2020, 156, 70-76.	1.4	37
67	Recurrent cervical cancer. Current Treatment Options in Oncology, 2002, 3, 105-111.	3.0	36
68	Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer. Gynecologic Oncology, 2019, 154, 60-64.	1.4	35
69	International radical trachelectomy assessment: IRTA study. International Journal of Gynecological Cancer, 2019, 29, 635-638.	2.5	35
70	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecologic Oncology, 2020, 156, 194-202.	1.4	35
71	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. Scientific Reports, 2020, 10, 17769.	3.3	35
72	Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome. Neoplasia, 2015, 17, 183-189.	5.3	33

#	Article	IF	CITATIONS
73	Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. Gynecologic Oncology, 2017, 146, 263-267.	1.4	33
74	Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma. Gynecologic Oncology, 2020, 157, 619-623.	1.4	32
75	Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. Gynecologic Oncology, 2017, 147, 115-119.	1.4	31
76	Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta-analysis of randomized clinical trials. Gynecologic Oncology, 2017, 144, 312-317.	1.4	31
77	The LACC Trial: Has Minimally Invasive Surgery for Early-Stage Cervical Cancer Been Dealt a Knockout Punch?. International Journal of Gynecological Cancer, 2018, 28, 1248-1250.	2.5	31
78	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. Gynecologic Oncology, 2018, 150, 44-49.	1.4	30
79	Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: Outcomes and impact on approach. Gynecologic Oncology, 2012, 125, 394-399.	1.4	28
80	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. International Journal of Gynecological Cancer, 2021, 31, 647-655.	2.5	28
81	Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. Modern Pathology, 2021, 34, 1008-1016.	5.5	27
82	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. PLoS ONE, 2020, 15, e0234505.	2.5	25
83	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Gynecologic Oncology, 2019, 154, 144-149.	1.4	24
84	Clear cell carcinoma of the endometrium. Gynecologic Oncology, 2022, 164, 658-666.	1.4	23
85	Cervical cancer in patients infected with the human immunodeficiency virus. Cancer, 2008, 112, 2683-2689.	4.1	22
86	The role of adjuvant therapy in uterine leiomyosarcoma. Expert Review of Anticancer Therapy, 2016, 16, 45-55.	2.4	22
87	Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers. Gynecologic Oncology, 2009, 115, 204-208.	1.4	21
88	Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. Cancer Medicine, 2018, 7, 2280-2287.	2.8	21
89	Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. American Journal of Obstetrics and Gynecology, 2022, 226, 97.e1-97.e16.	1.3	20
90	Risk factors for financial toxicity in patients with gynecologic cancer. American Journal of Obstetrics and Gynecology, 2022, 226, 817.e1-817.e9.	1.3	20

#	Article	IF	CITATIONS
91	Advances in the management of endometrial carcinoma. Gynecologic Oncology, 2011, 120, 489-492.	1.4	18
92	Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. Gynecologic Oncology, 2019, 152, 38-45.	1.4	18
93	Is Robotic-Assisted Surgery Safe in the Elderly Population? An Analysis of Gynecologic Procedures in Patients ≥ 65ÂYears Old. Annals of Surgical Oncology, 2019, 26, 244-251.	1.5	18
94	Sentinel Lymph Node Mapping in Patients with Endometrial Carcinoma: Less Can Be More. Current Obstetrics and Gynecology Reports, 2016, 5, 279-285.	0.8	16
95	Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. Annals of Surgical Oncology, 2020, 27, 3772-3780.	1.5	16
96	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecologic Oncology, 2021, 161, 535-544.	1.4	16
97	Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology, 2011, 120, 33-37.	1.4	15
98	Current and future surgical approaches in the management of endometrial carcinoma. Future Oncology, 2008, 4, 389-401.	2.4	14
99	Robotically Assisted Laparoscopic Ovarian Transposition in Women with Lower Gastrointestinal Cancer Undergoing Pelvic Radiotherapy. Annals of Surgical Oncology, 2017, 24, 251-256.	1.5	14
100	Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment. Gynecologic Oncology, 2018, 151, 395-400.	1.4	14
101	Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. Gynecologic Oncology, 2019, 154, 333-337.	1.4	14
102	The change in landscape after a new landmark is constructed: Radical hysterectomy for early cervical cancer and Minimally Invasive Surgery. Gynecologic Oncology, 2019, 153, 1-2.	1.4	14
103	Endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma with a background of complex atypical hyperplasia and final hysterectomy pathology. American Journal of Obstetrics and Gynecology, 2010, 202, 278.e1-278.e6.	1.3	12
104	Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget's Disease of the Vulva. JCO Precision Oncology, 2020, 4, 1054-1060.	3.0	12
105	Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study. Gynecologic Oncology, 2020, 159, 187-194.	1.4	12
106	Prophylactic Negative Pressure Wound Therapy After Laparotomy for Gynecologic Surgery. Obstetrics and Gynecology, 2021, 137, 334-341.	2.4	12
107	Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction - A proposed management algorithm. Gynecologic Oncology, 2021, 162, 262-267.	1.4	12
108	Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic Oncology, 2013, 128, 28-33.	1.4	11

#	Article	IF	CITATIONS
109	Impact of hospital volume on surgical management and outcomes for early-stage cervical cancer. Gynecologic Oncology, 2020, 157, 508-513.	1.4	11
110	Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer. Gynecologic Oncology, 2016, 140, 383-386.	1.4	10
111	The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. Gynecologic Oncology, 2021, 160, 99-105.	1.4	10
112	Brain metastases in patients with low-grade endometrial carcinoma. Gynecologic Oncology Reports, 2018, 26, 87-90.	0.6	9
113	Current and novel mapping substances in gynecologic cancer care. International Journal of Gynecological Cancer, 2020, 30, 387-393.	2.5	9
114	Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort. Gynecologic Oncology, 2021, 163, 294-298.	1.4	9
115	Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma. Gynecologic Oncology, 2022, 165, 287-292.	1.4	9
116	Operative management of primary epithelial ovarian cancer. Current Oncology Reports, 2007, 9, 478-484.	4.0	8
117	Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma. Brachytherapy, 2019, 18, 38-43.	0.5	8
118	The Landmark Series: Minimally Invasive Surgery for Cervical Cancer. Annals of Surgical Oncology, 2021, 28, 204-211.	1.5	8
119	Treatment of Extramammary Paget Disease and the Role of Reflectance Confocal Microscopy: A Prospective Study. Dermatologic Surgery, 2021, 47, 473-479.	0.8	8
120	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. Gynecologic Oncology, 2021, 162, 345-352.	1.4	8
121	Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer. Gynecologic Oncology, 2017, 147, 371-374.	1.4	7
122	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	3.0	7
123	Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer. International Journal of Gynecological Cancer, 2019, 29, 1377-1380.	2.5	7
124	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. Gynecologic Oncology, 2020, 158, 397-401.	1.4	7
125	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. Gynecologic Oncology, 2020, 159, 418-425.	1.4	7
126	Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancers. Gynecologic Oncology, 2010, 119, 208-211.	1.4	6

#	Article	IF	CITATIONS
127	Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs. Journal of Minimally Invasive Gynecology, 2019, 26, 727-732.	0.6	6
128	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. International Journal of Gynecological Cancer, 2020, 30, 1162-1168.	2.5	6
129	Factors Associated With Premature Ovarian Insufficiency in Young Women With Locally Advanced Rectal Cancer Treated With Pelvic Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100801.	1.2	6
130	Management of epithelial ovarian cancer. Clinical Advances in Hematology and Oncology, 2018, 16, 656-659.	0.3	6
131	Radical Hysterectomy for Cervical Cancer: the Right Surgical Approach. Current Treatment Options in Oncology, 2022, 23, 1-14.	3.0	6
132	Improving safety in robotic surgery: Intraoperative crisis checklist. Journal of Surgical Oncology, 2013, 108, 139-140.	1.7	5
133	Venous thromboembolism and minimally invasive surgery in gynecologic oncology: Time to re-evaluate and refocus. Gynecologic Oncology, 2014, 134, 217-218.	1.4	5
134	Non-exenterative surgical management of recurrent endometrial carcinoma. Gynecologic Oncology, 2021, 162, 268-276.	1.4	5
135	Preoperative CA-125 Levels in Patients with Hereditary Compared to Sporadic Epithelial Ovarian Carcinoma. Gynecologic Oncology, 2002, 84, 413-415.	1.4	4
136	Multiparametric magnetic resonance imaging facilitates the selection of patients prior to fertility-sparing management of endometrial cancer. Abdominal Radiology, 2021, 46, 4410-4419.	2.1	4
137	Pattern of disease and response to pembrolizumab in recurrent cervical cancer. Gynecologic Oncology Reports, 2021, 37, 100831.	0.6	4
138	Primary characteristics and outcomes of newly diagnosed low-grade endometrial stromal sarcoma. International Journal of Gynecological Cancer, 2022, 32, 882-890.	2.5	4
139	Vulvar melanoma: management of primary disease and repeated recurrences. International Journal of Gynecological Cancer, 2019, 29, 1077-1081.	2.5	3
140	Update on Sentinel Lymph Node Mapping in Endometrial Cancer Patients with a High Risk for Nodal Metastasis. Indian Journal of Gynecologic Oncology, 2020, 18, 1.	0.3	3
141	The current clinical approach to newly diagnosed uterine cancer. Expert Review of Anticancer Therapy, 2020, 20, 581-590.	2.4	3
142	Surveillance patterns of cervical cancer patients treated with conization alone. International Journal of Gynecological Cancer, 2020, 30, 1129-1135.	2.5	3
143	Post-LACC era: critical assessment not "all-or-none―is needed. Journal of Gynecologic Oncology, 2021, 32, e47.	2.2	3
144	Micropapillary Pattern in Newly Diagnosed Borderline Tumors of the Ovary: What's in a Name?. Oncologist, 2011, 16, 133-135.	3.7	2

#	Article	IF	CITATIONS
145	The aftershocks of the LACC earthquake have begun: brace yourselves. International Journal of Gynecological Cancer, 2020, 30, 157-159.	2.5	2
146	Monitoring vulvar melanoma response to combined immunotherapy and radiotherapy with <i>in vivo</i> reflectance confocal microscopy. JDDG - Journal of the German Society of Dermatology, 2021, 19, 768-770.	0.8	2
147	Immediate lymphatic reconstruction: the time is right to prevent lymphedema following lymphadenectomy for vulvar cancer. International Journal of Gynecological Cancer, 2021, 31, 943-943.	2.5	2
148	Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. International Journal of Gynecological Cancer, 2021, 31, 222-231.	2.5	2
149	Asian Society for Gynecologic Robotic Surgery consensus guidelines on robotic surgery in gynecological cancer. Gynecologic Robotic Surgery, 2020, 1, 2-13.	0.2	2
150	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. JCO Clinical Cancer Informatics, 2022, 6, e2100154.	2.1	2
151	Fertility-sparing surgery in gynecologic oncology. Expert Review of Obstetrics and Gynecology, 2008, 3, 211-221.	0.4	1
152	Clinical Approach to Diagnosis and Management of Endometrial Hyperplasia and Carcinoma. Surgical Pathology Clinics, 2011, 4, 113-130.	1.7	1
153	Improving Sentinel Lymph Node Detection in Patients with Cervical Cancer. Annals of Surgical Oncology, 2015, 22, 4115-4116.	1.5	1
154	Quaternary and beyond cytoreduction: An updated and expanded analysis. Gynecologic Oncology Reports, 2021, 37, 100851.	0.6	1
155	Endometrial Cancer Prevention. , 2014, , 593-611.		1
156	Metastatic melanoma concurrent to the urinary bladder and endometrium: Case report. Journal of Medical Imaging and Radiation Oncology, 2021, , .	1.8	1
157	Risk factors for postoperative wound dehiscence after skin repair: A case-control study. Journal of the American Academy of Dermatology, 2022, 87, 1099-1102.	1.2	1
158	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. Bladder Cancer, 2022, 8, 291-301.	0.4	1
159	In Reply. Obstetrics and Gynecology, 2013, 121, 877.	2.4	0
160	Radical Hysterectomy. , 2018, , 181-192.		0
161	Robotic Surgery. , 2018, , 364-380.		0
162	Robotic-assisted psoas hitch with ureteral reimplantation. International Journal of Gynecological Cancer, 2019, 29, 223-223.	2.5	0

#	Article	IF	CITATIONS
163	ASO Author Reflections: Robotically Assisted Gynecologic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. Annals of Surgical Oncology, 2020, 27, 3781-3782.	1.5	Ο
164	Global disparities in oncology: Pinpointing and addressing the causes. International Journal of Gynecology and Obstetrics, 2021, 153, 188-189.	2.3	0
165	Clinical outcomes of patients with endometrioid epithelial ovarian cancer following surgical treatment. Journal of Surgical Oncology, 2021, 124, 846-851.	1.7	0
166	Staging and Surgical Treatment. Cancer Treatment and Research, 2009, 149, 35-61.	0.5	0
167	Robotic Para-aortic Lymph Node Dissection. , 2018, , 131-140.		0
168	The end of routine lymphadenectomy for the treatment of cervical cancer is rapidly approaching. Gynecologic Oncology, 2022, 164, 461-462.	1.4	0
169	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
170	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
171	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
172	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0